NCT02898792View on ClinicalTrials.gov

Remifentanil in Adults With OSA

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 16, 2016

Primary Completion Date

May 2, 2018

Study Completion Date

May 2, 2018

Conditions
Apnea, Sleep
Interventions
DRUG

Targeted infusion of remifentanil

Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.

Trial Locations (1)

63110

Washington University St Louis School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02898792 - Remifentanil in Adults With OSA | Biotech Hunter | Biotech Hunter